Second-generation antipsychotics (SGAs), such as risperidone, clozapine and olanzapine, are the most common drug treatments for schizophrenia. SGAs presented an advantage over first-generation antipsychotics (FGAs), particularly regarding avoidance of extrapyramidal symptoms. However, most SGAs, and to a lesser degree FGAs, are linked to substantial weight gain. This substantial weight gain is a leading factor in patient non-compliance and poses significant risk of diabetes, lipid abnormalities (that is, metabolic syndrome) and cardiovascular events including sudden death. The purpose of this article is to review the advances made in the field of pharmacogenetics of antipsychotic-induced weight gain (AIWG). We included all published association studies in AIWG from December 2006 to date using the Medline and ISI web of knowledge databases. There has been considerable progress reaffirming previous findings and discovery of novel genetic factors. The HTR2C and leptin genes are among the most promising, and new evidence suggests that the DRD2, TNF, SNAP-25 and MC4R genes are also prominent risk factors. Further promising findings have been reported in novel susceptibility genes, such as CNR1, MDR1, ADRA1A and INSIG2. More research is required before genetically informed, personalized medicine can be applied to antipsychotic treatment; nevertheless, inroads have been made towards assessing genetic liability and plausible clinical application.
Introduction
The introduction of chlorpromazine in the 1950s provided the first effective pharmacological treatment of schizophrenia (SCZ), and established antipsychotics as the primary intervention of many psychiatric disorders. Numerous typical antipsychotics or firstgeneration antipsychotics (FGAs) were subsequently developed, and collectively demonstrated successful treatment of psychotic symptoms, in particular delusions and hallucinations. The benefits of FGAs were offset by the common occurrence of elevated prolactin and extrapyramidal symptoms (EPS), such as Parkinsonism and tardive dyskinesia. These medications were also severely limited by their inability to treat the full range of SCZ symptoms. In the early 1970s, clozapine was introduced as the first atypical antipsychotic or second-generation antipsychotic (SGA), which marked a significant advantage over typical medications in its decreased risks of causing neurological side effects, and increased efficacy of treatment. 1, 2 Since the introduction of clozapine, many SGAs have been developed, such as olanzapine and risperidone, although among SGAs, only clozapine shows an increased efficacy of treatment compared with FGAs. 3 Unfortunately, most SGAs, in particular clozapine and olanzapine, have been linked to substantial drug-induced weight gain, which confers risks of metabolic syndrome, diabetes mellitus type II and cardiovascular disease [4] [5] [6] ( Figure 1 ). Furthermore, antipsychotic-induced weight gain (AIWG) has consistently been associated with elevation of liver enzymes, suggesting that antipsychotics may be involved in hepatocyte damage. 7 SCZ patients have a 20% shorter lifespan compared with the general population, with cardiovascular disease being the leading cause of death. 8 Moreover, Goff et al. 9 reported a quadrupled increased incidence of diabetes (13 vs 3%) and double incidence of hypertension (27 vs 17%) in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) sample when compared with age-, race-and gendermatch controls from NHANES III (National Health and Nutrition Examination Survey III). In addition to the health risks of weight gain, social stigmatization of weight gain and obesity are major factors contributing to patient non-compliance 4, 10 ( Figure 1 ).
Typical and atypical antipsychotics
In general, most SGAs use a 'pharmacological shotgun' approach with strong affinity for the serotonin 5-HT 2 receptor with concomitant affinities for dopaminergic, muscarinic, histaminergic and adrenergic receptors. 11 In contrast, FGAs are generally more specific, and bind with greater affinity to the dopamine D2 receptor. It should be noted that there are exceptions to this generalization as a class of FGAs called phenothiazines (for example, chlorpromazine) have a more diverse binding profile, whereas SGAs such as risperidone and ziprasidone have high D2 and D3 antagonism. 12 Although SGAs have preferential action on 5-HT 2 receptors, the rapid dissociation of most SGAs from the D2 receptor has been suggested to account for the atypicality. 13, 14 SGAs constitute a major improvement in the avoidance of extrapyramidal symptoms through reduced D2 receptor occupancy. 15 Unfortunately, side effects such as weight gain and impaired glucose tolerance/ lipid abnormalities are observed. 4 However, the risk of weight gain is variable among SGAs (Figure 2 ). The mechanism of drug-induced weight gain is mostly unclear; receptor-binding profiles of these drugs have been implicated. For instance, the SGA amisulpride is a pure dopamine receptor D2/D3 antagonist that correlates with lower metabolic risks; moreover, both Figure 1 Factors and outcomes relating to antipsychotic-induced weight gain and personalized medicine. (a) The future of 'personalized medicine' in psychiatry requires consideration of pharmacogenetic screening and personal variables that may influence drug response for each individual antipsychotic used by each patient. Additional factors influence the efficacy of individualized DNA pharmacogenetic tests including genetic screens with sufficient sensitivity and specificity, biocomputational analysis to build an algorithm incorporating genetic and non-genetic factors (for example, neuro-fuzzy modeling), ethical challenges such as genetic discrimination due to the pleiotropic effects of gene variants, as well as education of physicians and caregivers to communicate genetic findings. (b) Antipsychotic-induced weight gain leads to cardiovascular disease, type II diabetes, hypertension and metabolic syndrome costs. Weight gain is also a leading factor in patient non-compliance, a major risk factor for relapse and rehospitalization. Finally, weight gain can cause stigmatization and difficulties in interpersonal relationships that may further alienate SCZ patients. (c) Both genetic (for example, CYP2D6, HTR2C and LEP genes) and non-genetic (co-medication, sedentary lifestyle and socio-demographic) factors may influence treatment-induced weight gain, including possible epigenetic factors. Figure 2 Meta-analyses values for mean and 95% confidence interval of weight change after FDA-approved antipsychotic treatment (up to 12 weeks). Sources of information: Parsons et al. 160 (olanzapine, risperidone, ziprasidone, haloperidol and placebo), Allison et al. 161 (clozapine, thioridazine, chlorpromazine, fluphenazine) and Marder et al. 162 (aripiprazole). 95% Confidence interval is unavailable for aripiprazole. the serotonin 5-HT 2 c-and the histamine H1-blocking activity have been associated with increased risk of metabolic abnormalities. 13 
Genetic factors
Genetic factors are among the strongest risk factors influencing AIWG. 4 For example, a recent twin and sibling study found AIWG to be heritable (h 2 = 0.6-0.8). 16 An understanding of the genetic factors involved in AIWG could allow for tailored treatment for at-risk individuals. However, the literature on the genetic contribution to metabolic side effects induced by antipsychotics has presented inconsistencies. Similar to other complex phenotypes, AIWG is likely to be polygenic with each polymorphism making a minor contribution to the overall phenotype. Furthermore, risk factors may vary between antipsychotic medications. Nevertheless, numerous compelling genes have come to the forefront, such as HTR2C, leptin and DRD2, and new susceptibility genes are being discovered as techniques for studying pharmacogenetics become more sophisticated.
Methods
We reviewed published association studies in AIWG from December 2006 to date, using the Medline database (http://www.ncbi.nlm.nih.gov/pubmed/) and ISI web of knowledge (http://apps.isiknowledge. com; for review of studies before 2006, see Mü ller and Kennedy 4 and Mü ller et al.
5
). Earlier studies were cited when they were important in the context of newer findings. The following search terms were included: antipsychotic, neuroleptics, body weight, weight gain, obesity, overweight, metabolic syndrome, BMI, therapeutic outcome, side effects, gene, genetics, pharmacogenetics and the name of each active antipsychotic medication together with weight gain, gene and other keywords. Conference abstracts were excluded, except for one important finding from the study by Lencz et al. 17 In our comprehensive review, all studies were considered regardless of differences with respect to ethnicities, age groups, diagnostic criteria and experimental designs. The majority of studied individuals were affected by SCZ or schizoaffective disorders with some studies also including healthy controls, first-episode psychosis, bipolar disorders and pediatric psychiatric patients. Multiple study design modalities were considered including candidate gene, tag-single nucleotide polymorphism (SNP) analysis, cross-sectional design, case and control and genome-wide association study (GWAS), in addition to variable length of study. Meta-analyses and studies combining previous investigations were considered as interim summaries of previous works. In total, 49 studies were selected for this review (Table 1) .
Pharmacokinetic studies
The role of drug metabolism and plasma drug levels has been emphasized in the efficacy of antipsychotic treatment and in the prevalence of side effects. The majority of atypical antipsychotics are metabolized by phase I cytochrome P450 (CYP450) isoenzymes. 4 Pharmacokinetic studies have hypothesized that poor CYP450 activity could be associated with increased serum levels of antipsychotics that may lead to increased weight gain. Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of risperidone; thus, polymorphisms in this gene may be associated with weight gain. The CYP2D6 gene is highly polymorphic with > 90 reported allelic variants. 18 In risperidone-treated patients, T-allele carriers of the 188C/T variant (CYP2D6*10) were reported to have significantly lowered CYP2D6 activity. Furthermore, the effect was largest among homozygote carriers. 19 The 188T allele of CYP2D6 was significantly associated with AIWG in a study of Han Chinese SCZ patients undergoing risperidone treatment. 20 More recently, the MDR1 gene has been a target of pharmacokinetic studies. MDR1 encodes for p-glycoprotein. P-glycoprotein is an ATP-dependent efflux pump that is expressed at blood-tissue barriers and tissues involved in normal excretory function. 21 It limits the absorption of orally administered drugs, promotes drug elimination into bile and urine, as well as limits transport to various tissues. 22 The T alleles of the C2677T and C3435T polymorphisms were significantly associated with weight gain in risperidone-and olanzapine-treated women (P = 0.015 and P = 0.031, respectively). 22 In contrast, an earlier study yielded no significant results, although the smaller sample size of this study may not have had sufficient statistical power to detect an association (Table 2 ). 23 The notion that variation in drug-metabolizing enzyme activity and neural transporters may have a role in AIWG is intriguing, especially with regard to personalized medicine. Thus far, the pharmacokinetic genes have been suggested to be simpler traits than genes involved in pharmacodynamics. 24, 25 However, it remains unclear whether plasma concentrations of SGAs correlate with weight gain. Randomized controlled trials generally fail to demonstrate any relationship between weight gain risk and dose for clozapine, olanzapine and risperidone. 26 Conversely, quetiapine dosage may be connected to both frequency and magnitude of weight gain, and results from long-term trials of risperidone are controversial. 26 The extent to which pharmacokinetic genes may predict AIWG or its efficacy is still largely undetermined. A recent outcome from the CATIE study suggests that genetic determinates of variable drug metabolism (CYP450, MDR1, flavin-containing monooxygenase 3) have little impact on the clinical use of antipsychotic medication. 27 Epigenetic and micro-RNA-dependent control of pharmacokinetic genes would provide another layer of information. The major drug-metabolizing enzyme of olanzapine and clozapine, CYP1A2, has been shown to have the expected inverse correlation between DNA 28 Thus, epigenetic and genetic analyses of CYP1A2 may give a more detailed picture of the potential relationship between antipsychotic metabolism and weight gain. However, the field of pharmacoepigenetics is in its infancy with its focus almost entirely on cancer treatments.
In conclusion, there is a paucity of research relating to pharmacokinetic genes and AIWG. Further molecular genetic analyses of pharmacokinetic genes such as the CYP450 and MDR1 genes are warranted to understand the clinical utility of these genes in the development of a more personalized therapy.
Pharmacodynamics
Monoamine influence on homeostatic balance Serotonin system. The serotonin system has been the focus of numerous studies as SGAs that are associated with the highest risk of weight gain strongly antagonize serotonin (5-HT) receptors. Serotonin receptors are strong targets of SGAs as revealed by neuroimaging studies that showed high occupancy of 5-HT 2 receptors by SGAs. 29 Moreover, genetic variants in the 5-HT 2 receptor genes have been strongly linked to response to clozapine and risperidone. 20, 22, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In addition, 5-HT receptors influence central pathways affecting satiety and hunger. The 5-HT agonist, d-fenfluramine, is a potent appetite suppressant. Moreover, both animal and human studies report strong evidence that 5-HT levels and pro-satiety signaling are positively correlated. 40 Of the serotonin receptor genes, the HTR2C has been the most extensively studied gene in AIWG. The rs3813929 (C/T) promoter SNP (À759C/T) of the X-linked HTR2C gene is one of the most consistent markers associated with AIWG. The rs3813929 variant is likely to have functional significance; however, interpretation of the functional activity is difficult. Two studies have reported that the C allele of rs3813929 decreases transcriptional activity. 41, 42 However, a subsequent study by McCarthy et al. 43 failed to replicate these earlier findings, and a more recent paper by Hill and Reynolds 44 found the T allele to reduce promoter activity. Thus, the true effects of this polymorphism and transcriptional activity have to be further elaborated as these conflicting results are likely due to different cell lines and variable promoter haplotypes examined. It remains unclear how receptor expression is related to AIWG. Nonetheless, we believe it is interesting that functional studies have been conducted, and that despite conflicting findings, some significant results have been obtained. Furthermore, it is unclear to which extent these cell lines can be used to explain the variable expression of HTR2C in different regions of the brain, and the role of RNA editing (see below). It is also important to note that the rs3813929 variant may have less importance in African-American populations because of the lower minor allele frequency (Hapmap release no. 27: 45 African ancestry in Southwest USA (ASW) T-allele frequency = 0.035). Nonetheless, the rs3813929 promoter polymorphism has been the most heavily studied variant, and may provide the best evidence for AIWG. An additional variant in the HTR2C gene, the rs6318 (Cys23Ser) SNP may disrupt a disulfide bridge, which suggests functional significance. 46 Since 2006, 15 studies of 12 polymorphisms in four 5-HT receptor genes (namely HTR1A, HTR2A, HTR2C and HTR6) have been reported. 32, 33 The rs3813929 variant of HTR2C was reported to be associated with weight gain in five studies; 20, 34, 37, 47, 48 however, six additional studies have not been able to associate the variant with change in body mass. 22, 30, 35, 38, 39, 49 An additional promoter variant in the HTR2C gene, rs518147 (À697C/G) 47 and the combined haplotype (c.1-11429(GT)n 13 repeat (13R), À759C/T and 401C > G) were associated with the risk of obesity and metabolic syndrome. 32, 33 However, studies of rs6318 have yielded inconclusive 38 (a = association with AIWG; m = association with metabolism dysregulation; f = functional significance). Cross-sectional study olanzapine (67) risperidone (101) 168 Mostly European American rs7412 associated with weight gain in olanzapine patients (P = 0.0056) 115 BDNF rs6265 (66Val/Met) > 10 Years treatment clozapine (98) risperidone (36) perphenazine (20) haloperidol (19) chlorpromazine ( (25) olanzapine (22) risperidone (14) quetiapine (6) aripiprazole (6) haloperidol ( 
DRD2
Tag-SNPs (13) 48.2±27. (25) olanzapine (22) risperidone (14) quetiapine (6) aripiprazole (6) haloperidol ( Cross-sectional study olanzapine (67) risperidone ( (24) olanzapine (33) risperidone (8) amisulpride (2) quitiapine (2) mixed (52) SCZ or SA: 128 European (118) Turkish ( Cross-sectional study olanzapine (67) risperidone (101) 168 Mostly European American rs4765626 associated with weight profile in olanzapine (P = 0.015) 115 Pharmacogenetics of AIWG TAP Lett et al 50 The 102T/C polymorphism of the HTR2A gene was significantly associated with weight gain in patients receiving olanzapine and risperidone treatment in Japanese and Han Chinese samples (P < 0.0001 and P = 0.0049, respectively). 20, 38 A haplotype-type analysis in a limited sample size (N = 46, White Europeans) reported association between C peptide levels and À1438A, À102T and 452His haplotypes, but not a change in body mass index (BMI), suggesting that further research is required to establish the potential role of HTR2A in AIWG ( Table 2) . 31 Finally, a single variant of the HTR1A gene was negative in a Han Chinese population (Table 2 ). 20 The negative findings for the HTR2C receptor gene were in studies with patients undergoing extensive previous treatment, which may explain the inconsistencies across results. The association between rs3813929 and AIWG tended to be significant in studies with short treatment duration ( < 3 months), and less or not significant in long-term studies ( > 3 months; Table 3 ). Furthermore, in studies of European-American patients treated predominantly with clozapine or olanzapine, a significant association was reported, although the association was not observed in an Asian or an African-American population. The negative finding in African Americans may be expected due to the lack of variation of the rs3813929 SNP in that population. There may be an additional level of control of the HTR2C that could explain the lack of association in European Americans and Asians. The HTR2C gene has a unique feature in that RNA editing may dynamically regulate receptor activity, 51 and that this pattern of editing is altered in animals treated with antipsychotics. 52 Taken together, meta-analyses have repeatedly reaffirmed that the C allele of this SNP poses a clinically significant risk for weight gain. 30, 53, 54 In a meta-analysis, De Luca et al. 30 reported a slight association of rs3813929 with weight gain, and however noted significant heterogeneity across samples. A more recent meta-analysis of 10 independent studies confirmed this association. 54 The positive result for the 102T/C polymorphism of the HTR2A gene suggests that additional 5-HT receptors can be involved in weight gain. These promising findings should serve as a stimulus for future research, especially with the advent of new research techniques and decreasing cost of analysis.
The dopamine system. The role of dopamine in mediating antipsychotic response is well documented. Accumulating evidence suggests that targeting of dopamine by all antipsychotic medications is associated with amelioration of positive symptoms. Positron emission tomography studies reveal that a minimal occupancy of 60% of striatal dopamine D2 receptors is required for clinical response, whereas blockade > 80% may be the main cause of EPS. 15, 55 However, striatal dopamine D2 receptor availability was found to be significantly lower in obese individuals compared with controls. 56 Furthermore, disruption in the dopamine D2 receptor gene (DRD2) was reported to be associated with obesity. 4, 5 Dopamine modulates motivation and central reward circuitry, and thus, deficiency in dopamine transmission through dopamine antagonism may perpetuate increased eating to compensate from a blunted reward circuitry. Although dopamine antagonisms are such an integral part of antipsychotic efficacy, only recently has evidence emerged that the dopamine system may be involved in weight gain side effects.
Initial analyses by Lane et al. 20 of five polymorphism in the D1, D2 and D3 dopamine receptor genes (DRD1, DRD2, DRD3) were unsuccessful in discovering an association between risperidone and AIWG ( Table 2 ). In contrast, recent studies using tag-SNPs have implicated variants for DRD2 and variablenumber tandem repeats (VNTRs) of the dopamine receptor D4 (DRD4) in AIWG. In a long-term study by ST, short term ( < 3months). þ or À = Significant or non-significant association with SGA-induced weight gain, respectively. a These denote patients treated with solely or mostly olanzapine or clozapine.
Hong et al., 57 tag-SNP analysis of the DRD2 gene found that the C allele of rs4436578 was strongly associated with weight gain (P = 0.003, OR = 3.36 (1.62-7.00)) in 479 Chinese SCZ patients undergoing clozapine, olanzapine and risperidone treatment. The À141C Ins/Del (rs1799732) has previously been associated with decreased efficacy of antipsychotic treatment 58, 59 and may alter D2 receptor density; 60, 61 however, the direction change in density remains controversial. Thus, it remains difficult to interpret the biological significance at the present time.
One recent longitudinal study of first-episode SCZ reported that rs1799732 was associated with more weight gain (P = 0.024), 62 and further examination of this variant is warranted to confirm this result. Furthermore, our group examined 36 tag-SNPs and 1 VNTR spanning 5 dopamine receptors (DRD1-DRD5) in 206 chronic SCZ or schizoaffective disorder patients. 63 The DRD2 rs1079598 marker was associated with weight gain (P = 0.03). When stratifying according to ethnicity and antipsychotics (that is, Europeans treated with clozapine or olanzapine), associations were observed in three DRD2 SNPs: rs6277 (957C/T), rs10779598 and rs1800497 (Taq1A). This is consistent with a previous association between rs1800497 and obesity. 64, 65 Moreover, the association of the rs6277 marker is particularly interesting because the rs6277T allele is associated with decreased striatal D2 affinity in vivo, and in vitro analysis revealed decreases in mRNA stability and half-life. 66, 67 Our group also observed the rs6277C allele to be associated with an increased risk of tardive dyskinesia. 68 Therefore, the rs6277 polymorphism could have a broader association with antipsychotic tolerance, whereas the rs6277C allele carriers may be exposed to higher risk of adverse events.
The expression of the dopamine D4 receptor is elevated in patients suffering from SCZ, 69 and D4 receptors are more strongly targeted by clozapine. 70 The hypofunctional 7-repeat (7R) allele of DRD4 exon 3 VNTR has been associated with maximal BMI in bulimia nervosa. [71] [72] [73] Our group did not find a significant association with weight gain; 63 however, a prospective study by Popp et al. 36 of 102 antipsychotic-naive, European-American inpatients, did discover that 7R carriers conferred greater weight gain (P = 0.003). The role of the 7R allele as a potential risk marker for antipsychotic-naive patients awaits replication and should be an interesting avenue for future research.
In summary, previous findings in the dopaminergic system have only recently received more attention and warrants further investigation. The future direction of research should be directed towards: (1) confirming these novel findings, (2) gene expression studies to examine the functional significance (such as the rs4436578 and rs1079598 variants of DRD2) and (3) examining other genes involved in dopamine signal transmission. These initial findings strongly suggest that other genes related to dopamine neurotransmission should be examined. For example, the functional VNTR variant of the dopamine transporter gene (DAT1) has been associated with response to the dopamine receptor agonist methyphenidate, 74 but not in antipsychotic efficacy. 75 The DAT1 VNTR is also associated with appetite suppression and binge eating. 76 Taken together, these findings lend strong rationale that DAT1 may be involved in AIWG, regardless of the lack of association with antipsychotic response. In general, we expect that the dopamine system will have a greater role in AIWG than early studies have suggested.
The adrenergic system. Most antipsychotics have relatively strong affinities for a1-and a2-adrenergic receptors. The adrenergic system is hypothesized to affect cognition and emotion, although very few pharmacogenetic studies have reported any genetic variation that contributes to treatment response. 77 However, adrenergic receptors are expressed ubiquitously in the body, and there is a strong evidence indicating that the ratio of a2-to b3-adrenergic receptors in the adipose tissue influences obesity through adipocyte hyperplasia. 20, 78 The contribution of the adrenergic system to AIWG has previously been understudied, although more recent findings suggest a greater role.
The ADRA1A gene was non-significant in two independent studies of four polymorphisms in Caucasian and Han Chinese populations. 79 However, Liu et al. 80 used tagging SNPs to strongly characterize the ADRA1A gene and demonstrated that numerous variants were associated with SGA-induced weight gain in a long-term, prospective study of 394 Chinese SCZ patients. This tag-SNP analysis showed evidence that the majority of significantly associated SNPs were located in the promoter and intron regions, and that the effect was enhanced in females. Positive results have also been observed in ADRA2A and ADRB3 genes. Park et al. 79 reported that the C-allele carrier of the À1291G/C (rs1800544) polymorphism of ADRA2A gained significantly more weight in olanzapine-treated Korean patients (P = 0.013). Furthermore, our group found that in mostly clozapine-or olanzapine-treated SCZ patients, rs1800544 was significantly associated with European Americans (P = 0.013), but not in African American patients 81 ( Table 2 ). The involvement of the 64 Try/Arg SNP (rs4993) of the ADRB3 gene in obesity, diabetes and hypertension has been well documented; 82 however, only a single study had significantly associated rs4993 and BMI in Japanese SCZ patients (P = 0.024). 38 In general, the adrenergic system has been comparatively understudied, and the role of adrenergic receptors in AIWG is unclear. All of the preceding ADR genes have been implicated in obesity and AIWG. This is in accordance with other obesityrelated genes like the leptin and melanocortin 4 receptor genes (Table 2) . However, unlike other strongly associated obesity-associated genes (for example, FTO), the protein products of these genes are directly or indirectly affected by antipsychotic actions. Thus, study of these obesity-and antipsychotic-related genes are paramount to understand AIWG, whereas genetic variation in other obesity-related genes may best explain baseline weight profiles. The tag-SNPs analysis of the ADRA1A gene and positive findings in the ADRA2A and ADRB3 genes suggests that all of these genes increase liability for AIWG; nonetheless, further study is required to confirm their risk profiles. For instance, the ADRA2A and ADRB3 genes have only been studied in clozapine-or olanzapine-treated populations; hence the effect is undetermined on antipsychotics with a smaller weight profile. Moreover, the effect of the ADR genes in AIWG is unclear across different ethnicities as the majority of the studies were performed in Asian populations.
The histamine system. The histaminergic system has an important role in reducing food intake and energy regulation through histamine-induced activation of the histamine receptors. For example, the potency of antipsychotic medications in blocking the histamine-1 (H1) receptor has been reported to correlate with their tendency to stimulate weight gain, 83 and deletions of the histamine-1 receptor gene abolish weight gain in SGA-treated mice. 84 Furthermore, H1 receptor agonists, such as olanzapine, activate hypothalamic AMP-activated protein kinase (AMPK1) that has been linked to the regulation of food intake, and reverse the actions of the anorexigenic hormone leptin. 85 Therefore, histamine may have been considered a compelling candidate for treatment-emergent weight gain; however, only one study has examined histamine receptors 1, 2 and 3 obtaining negative findings (Table 2) , although their sample size was limited. 38 Steen and colleagues 86 examined the five-receptor subunits of AMPK using tag-SNPs. Of the markers examined, only the rs10074991 polymorphism of the PRKAA1 subunit (AMPK) was associated with weight gain ( Table 2) . The histaminergic system has not yet been exhaustively studied, and despite negative findings of the histamine receptors, this remains an interesting avenue for future research. In particular, the downstream signaling pathway of histamine receptors seems to be an appealing candidate for future research.
Secondary effects of antipsychotic medication
The G-protein system. Monoamine receptors (for example, serotonin and dopamine receptors) signal to effector proteins through intracellular heterotrimeric G-protein subunits (a, b, g ). The G-protein beta-3 subunit (GNB3) gene has been previously associated with hypertension and obesity. [87] [88] [89] [90] [91] [92] [93] [94] In addition, the 825C/T splice variant of GNB3 (rs5443) 88 was a successful predictor of weight reduction in patients undergoing sibutramine therapy. 95, 96 Three studies have investigated the relationship between GNB3 825C/T SNP and AIWG. The 825T allele was associated with weight gain in an Asian olanzapinetreated population (P = 0.043); 38 however, negative results were reported in two studies with smaller sample sizes (Table 2) . 97, 98 The apparent association between the 825C/T SNP and metabolic side effects suggests that further analysis with an increased sample size for the GNB3 gene is justified, with more detailed analysis of other regions of the gene.
Synaptic signaling. The synaptosomal-associated protein of 25kDa (SNAP-25) is one of the three proteins involved in forming the soluble N-ethylmaleimide-sensitive protein receptor (SNARE). SNAREs form a complex that functions in vesicle trafficking at the presynaptic membrane, thereby modulating the release of neurotransmitters. 99 SNAP-25 is expressed in the islet of Langerhans (pancreatic b-cells) and is involved in insulin release. 100, 101 Furthermore, SNAP-25 is located in insulin-responsive tissues and therefore may affect lipolysis. 102 As intercellular signaling has an intricate link to the homeostatsis of hunger/satiety, six gene variants in the SNAP-25 gene have been analyzed in three studies.
In an initial study of the SNAP-25 gene by our group, two polymorphisms, rs3746544 (MnlI T/G) and rs8636 (TaiI T/C), were associated with both antipsychotic drug response and drug-induced weight gain; however, the rs1051312 (Ddel T/C) SNAP-25 polymorphism was not significant. 103 Musil et al. 104 reported an association between rs3746544 and rs8636 and serum triglyceride levels. The rs1051312 polymorphism was associated with increased in BMI after 5 weeks of SGA treatment. The fact that the results of SNAP-25 polymorphisms are only partially replicated may be due ethnicity and shorter observation time in the latter study. In addition, three other polymorphisms (401C/T, 1065T/ G and 1069T/C) were not significant in a Japanese sample, and 401C/T was monomorphic. 38 However, this study was the first examination of SNAP-25 markers in an Asian population.
SNAP-25 polymorphisms may well impact weight gain and potentially the development of metabolic syndrome during antipsychotic treatment. This potential impact is further supported by the independent findings of the role of SNAP-25 in pancreatic insulin release and peripheral insulin sensitivity. Further studies are required in larger samples that are prospectively analyzed to elucidate the exact role of rs3746544, rs8636 and rs1051312 markers in weight gain and dyslipidemia.
Appetite regulators
Leptin. Leptin is a peptide hormone secreted exclusively by the adipose tissue that acts at the level of the hypothalamus by binding to its receptor, and activating secondary signals. These secondary signals inhibit food intake and increase energy expenditure. 105 High serum leptin inhibits neuropeptide Y (NPY) mRNA expression, 105 and
Pharmacogenetics of AIWG TAP Lett et al stimulates the release of a-melanocyte-stimulating hormone (a-MCH). 106 This effect leads to appetite suppression, energy storage and insulin secretion (Figure 3) . Therefore, the gene encoding the leptin protein and its receptor has generated interest in pharmacogenetic studies of AIWG.
The rs7799039 (À2548A/G) promoter variant of leptin is proximal to a binding site for the transcriptional factor SP1. The transcriptional repressor, nucleolin, can bind to SP1 or its consensus site. 107 Thus, the presence of the A/A or A/G genotype corresponded with high and intermediate leptin mRNA expressions, respectively, whereas the G/G homozygote expressed low mRNA levels. 107, 108 Three studies examining Asian populations found the variant allele (G) or genotype (GA) to be associated with AIWG. [109] [110] [111] Zhang et al. 110 reported in further analysis that this association was significant in males but not in females. Similarly, Gregoor et al. 112 found the GG genotype to be significantly associated with weight gain in European males and the AA genotype in females, suggesting a potential sex-specific effect (Table 2) . In an analysis of risperidone-treated adolescents (7-17-years old), Calarge et al. 113 found the A allele to be associated with a steeper increase in BMI z-scores. The disparity between these studies remains unclear, but could be explained by different risk factors involved in AIWG between adults and children or ethnicity differences.
The rs1137101 (223Gln/Arg) polymorphism of the leptin receptor (LEPR) gene has also been studied. The presence of the 223Arg allele has been associated with lower obesity risk in risperidone-treated adolescents. 112 One small study which measured olanzapine plasma levels in 37 European-American patients found that carrying the 223Arg or À2548G alleles conferred risk of weight gain only in the subgroup of patients with high olanzapine plasma levels. 114 In a cross-sectional study using a physiogenomic approach, Ruañ o et al. 115 reported the rs817983 (656N/K) SNP of LEPR to be associated with weight gain resulting from risperidone but not from olanzapine treatment (P = 0.001). In summary, the leptin system has not yet been investigated exhaustively; however, several positive findings in the functional promoter À2548A/G polymorphism of the leptin gene, as well as 223Gln/Arg polymorphisms in its receptor, should act as incentive for future research.
The melancortin-4 receptor. The melanocortin-4 receptor (MC4R) is a seven-transmembrane G protein-coupled receptor expressed in the central nervous system, primarily in the hypothalamus. MC4R is a key regulator of the leptinergic control of energy homeostasis. 116 For example, MC4R activation of downstream effectors such as brain-derived neurotrophic factor (BDNF) results in decreased food intake and increased energy expenditure (Figure 3) .
Heterozygous coding mutations in MC4R are implicated in 0.5-6.3% in severe or early-onset obese populations, making it the most frequent cause of monogenic forms of human obesity. [117] [118] [119] A common genetic variant located 188 kb downstream of the MC4R gene (rs17782313) has been associated with increased fat mass, weight and risk of obesity. 120, 121 Furthermore, rs17782313 has been associated with higher intake of total energy and dietary fat, resulting in greater long-term weight change in a healthy population. Recently, a GWAS of AIWG in a drug-naive pediatric population identified one highly significant marker that overlaps the region previously identified by a large-scale GWAS of obesity (P = 2.8 Â 10
À7
, N = 270; Table 2 ). Our group subsequently replicated this finding in two independent samples consisting of adults receiving SGA treatment (P = 1.4 Â 10
À4
, N = 73; P = 0.007, N = 40; Table 2 ). Furthermore, each replication showed the same directions of risk alleles and genotypes for weight gain (risk allele homozygotes conferred B9 kg of weight gain vs 4 kg in heterozygotes and non-risk allele carriers). The two consecutive replications of this marker and the similar distribution of weight gain is highly indicative of a true association with AIWG.
14 This 'high-interest' finding implicates the MC4R gene region in AIWG, and further investigations are necessary to fully characterize the contribution of MC4R (as well as potential unidentified genes) in this region of this SNP. In addition, this region may contain previously undiscovered non-coding RNA that post-transcriptionally regulate MC4R expression or in guiding RNA modification. 122 Brain-derived neurotrophic factor. BDNF regulates survival and development of neurons, with important effects on neurogenesis and plasticity. 123 Neurodevelopmental models of SCZ implicate reduced BDNF levels in the central nervous system, and BDNF levels seem to be altered by the use of antipsychotics, 124, 125 and also numerous studies indicate that BDNF regulates energy expenditure. 126 The functional 66Val/Met polymorphism (rs6265) has been extensively studied for association with mental illness and cognitive function. 127 However, recent candidate gene studies have suggested a role in eating behavior 128 and BMI, 129 and the association between rs6265 and BMI has been replicated in a GWAS (P = 5.1 Â 10
À10
; effect size = 4.58±0.73). 130 Therefore, the BDNF gene has been shown to be associated with psychiatric disorders, altered by antipsychotic treatment and influence weight gain, thereby making BDNF an ideal candidate for pharmacogenetic research on AIWG.
However, only two groups have investigated this functional variant for association with AIWG in Chinese populations. The 66Met/Met genotype was associated with lower weight gain in Chinese SCZ patients (P = 0.02). 20 This finding was replicated in a subsequent study, however, only in males (P = 0.01). 131 Taken together, BDNF has been understudied to date, and future study would benefit from further examination of the BNDF gene in more ethnic groups and more variants. For example, the rs925946 SNP has also been strongly associated with weigh gain and change in BMI (P = 8.5 Â 10 À10 ; effect size = 3.85 ± 0.63). 130 Neuropeptide Y. Neuropeptide Y is a peptide neurotransmitter secreted by the hypothalamus for regulation of appetite and energy expenditure (Figure 3) . NPY agonists such as dexamethasone have been reported to increase food intake in rats. Moreover, blockage of the Y1 and Y5 NPY receptors decreases food intake through inhibition of NPY. 132 Given that the NPY and its receptors have an intimate role in energy homeostasis, Ruañ o et al.,
115 studied polymorphisms in the NPY gene (rs1468271) and in the NPY5R gene (rs6837793, rs11100494). It was reported that rs6837793 was associated with weight gain in risperidone-(P = 0.0024) but not in olanzapine-treated patients (Table 2) . Although preliminary, these findings seem interesting and should be addressed in further research.
Pro-melanin-concentrating hormone. The pro-melaninconcentrating hormone (PMCH) gene encodes the precursor to a-MCH. Animal studies have reported that the PMCH protein regulates food intake and energy homeostasis, 133 and PMCH knockout mice were found to be hypophagic. 134 Results from linkage study of obesity as a potential secondary effect of antipsychotics point to chromosome 12q24, including the PMCH gene. 135 A long-term follow-up case-control study in the same sample reported the rs7973796G allele of the PMCH gene to be associated with increased BMI compared with controls (P = 0.025). 136 Subsequent studies are required to verify the association between the PMCH gene and AIWG.
Ghrelin. Ghrelin is a gastric hormone with a potent orexigenic effect; that is, it mediates perception of hunger and/or appetite for meal initiation through receptors in the hypothalamus (Figure 3 ). Atypical antipsychotic medications have been found to decrease morning fasting ghrelin levels in the first 2 weeks of treatment, but to increase ghrelin levels in longer treatment durations. 106 Two studies have reported negative results with two independent variants in the ghrelin gene, although their relatively small sample sizes and poor coverage of the genetic variability in this gene does not negate its potential role in antipsychotic-induced weight gain (Table 2) . 38, 115 Endocannabinoids. The endocannabinoid system modulates energy balance by tonically reinforcing motivation to find and consume food, and transiently regulating orexigenic and anorexic mediators in the hypothalamus. 137 Cannabinoid receptor 1 (CNR1) agonists increase food intake and body weight, whereas antagonists lead to weight loss. 138 On the basis of these findings, our group analyzed tag-SNPs covering the CNR1 gene and found the rs806378T allele to be associated with SGA-induced weight gain in European Americans (n = 117; P = 0.008), but not in African Americans (n = 55). 139 We then conducted electrophoretic mobility shift assays showing that the presence of the T allele created a binding site for the transcription factor arylhydrocarbon receptor translocator (ARNT), implying functional significance. ARNT forms heterodimers with another transcription factor SIM1 that has been associated with monogenic forms of obesity, and is essential for differentiation of paraventricular nucleus in the hypothalamus. Another study investigating the synonymous polymorphism rs1049353 was negative 140 ( Table 2) . Two studies have also investigated the endocannabinoid-degrading enzyme, FAAH (fatty acid amide hydrolase). The 129Pro/Thr polymorphism (rs324420) was not significant in an Asian population. 38 In contrast, genotype and allele associations were reported for rs324420 (P = 0.004 and P = 0.002, respectively) in European Americans, 140 suggesting that the FAAH gene may predispose patients to clinically significant SGA-induced weight gain.
In summary, the endocannabinoid system is a novel and promising candidate in explaining antipsychoticinduced weight gain. Our findings in the CNR1 gene are especially interesting as the gene was well covered by tag-SNPs, and a possible functional significance was demonstrated for the rs806378T allele. Results in the FAAH gene are suggestive of an association with weight gain. However, the positive finding was conducted in a small number of patients, and all of the above observations need to be replicated in larger samples.
Lipid metabolism Cellular lipogenesis pathways. Antipsychoticinduced stimulation of cellular lipogenesis has been proposed as another possible explanation for dyslipidemia and weight gain. 4 Clozapine and chlorpromazine have been shown to be the strongest activators of sterol regulatory element-binding protein transcription activators, whereas ziprasidone had a minimal effect. 141 Le Hellard et al. 142 used a functional convergent genomic approach to investigate the role of five genes involved in the sterol regulatory element-binding protein activation of fatty acids and cholesterol production (SREBF1, SREBF2, SCAP, INSIG1 and INSIG2). The 201G/T (rs13223383) polymorphism of the INSIG1 gene was associated with weight gain (P = 0.005), and a strong association between clozapine and the INSIG2 gene was found for three tag-SNPs (rs17587100, rs17047764 and rs889904; P = 0.0003-0.00007). 142 However, two subsequent studies in more heterogeneous populations on mixed medications were not able to replicate these results 34, 143 ( Table 2 ). The mixed findings in the INSIG2 gene may be due to limited power in the latter two studies; therefore, further replication studies are necessary to understand the influence of INSIG2 in AIWG.
High-density and low-density lipoprotein pathways. Patients receiving atypical antipsychotic treatment are known to be at greater risk for elevations in serum triglycerides and glucose. Apolipoproteins are proteins that bind to lipids to facilitate their transport and regulate their metabolism. In a study of the contrasting mechanism of olanzapineand risperidone-mediated weight gain, olanzapine was associated with lipid dysregulation. The apolipoprotein E (APOE) gene is essential for normal catabolism of low-density lipoprotein. The rs7412 (176Arg/Cys; e2 allele) marker of APOE was found to be associated with weight gain induced by olanzapine (P = 0.0056; OR = 1.42). 115 Two genes involved in highdensity lipoprotein modulation were also found to be associated with olanzapine-induced weight gain: apolipoprotein A IV (APOA4), and the scavenger receptor class B, member 1 (SCARB1) (P = 0.0116, OR = 1.17; P = 0.015, OR = 1.05, respectively). A significant association was observed for the paraoxoase 1 (PON1) gene in risperidone-treated patients and a nominal association scavenger receptor class B, member 2 (SCARB2) (P = 0.0012, OR = 0.85; P = 0.0224, OR = 1.38, respectively). 115 Another study of 154 SCZ patients from Northern India found a significant haplotype associated with olanzapine-induced weight gain of the lipoprotein lipase gene (rs285C-rs320T-rs326-A-rs328C-rs4922115G: P = 0.005, OR = 2.26 (1.26-4.05), but no SNP alone was associated with weight gain. 144 No other significant associations were found in the lipid metabolism genes examined ( Table 2) .
The reported findings in the low-and high-density lipoprotein pathways are intriguing, especially considering that the APOC3, APOA5 and LPL genes have been found to alter serum lipids in SCZ patients undergoing FGA or SGA treatment. 145 Elevated triglycerides are a hallmark of pre-diabetes, and further study of these pathways could elucidate the relationship between AIWG and disorders such as metabolic syndrome and diabetes mellitus type 2.
Tumor necrosis factor alpha. Tumor necrosis factor alpha (TNFa) is a proinflammatory cytokine with endocrine function that has been associated with adipogenesis, obesity, insulin resistance and lipid metabolism. 4 Moreover, elevated levels of TNFa have been associated with clozapine treatment, making TNF a reasonable candidate gene. 146, 147 In an initial study in our group, the rs1800629 (À308A/G) promoter polymorphism of TNF was negative 148 ( Table 2 ). However, positive signals were observed in 55 clozapine-treated patients in an 8-year longitud inal study (P = 0.0084). 149 An additional marker in the gene encoding TNFa receptor 1A was not significant. 38 Investigations of rs1800629 and other polymorphisms are required to determine the influence of TNF in antipsychotic-induced weight gain, especially regarding potential long-term effects.
Genome-wide association studies GWAS in AIWG. Only one GWAS was published on metabolic side effects of antipsychotic medication. Adkins et al. 150 reported some promising findings in the CATIE sample. The most interesting finding was a significant association between an SNP in the MEIS2 gene (Meis homeobox 2) and waist and hip circumference under risperidone treatment. However, no polymorphisms reached genome-wide significance for changes in BMI.
GWAS in obesity.
Recently, GWASs in obesity have implicated numerous gene variants with changes in BMI and weight gain. Markers within or close to SH2B adapter protein 1 (SH2B1) and fat mass and obesity-associated (FTO) genes have been strongly associated with changes in body mass. 130, 151 GWASs in obesity have implicated numerous gene variants with changes in BMI and weight gain. Markers within or close to SH2B1 and FTO genes have been strongly associated with changes in body mass 152 and FTO 86, 152 genes not to be associated with AIWG (Table 2) . Nonetheless, these genes represent interesting candidates for future studies.
Discussion
Antipsychotic drugs are the primary treatment for psychotic disorders and are widely prescribed to most schizophrenic patients, often lifelong. Despite their benefits in alleviating many symptoms of SCZ, AIWG is undoubtedly of major clinical concern for many patients. Unfortunately, a single reliable predictor of weight gain has not been found. The promoter polymorphism of rs3813929 (À759 C/ T) in the HTR2C gene and the rs7799039 (À2548G/A) of the leptin gene are the most consistently associated variants with AIWG. This trend is concurrent with previous reviews, 4, 6 and meta-analyses in the HTR2C gene. 54, 153 The three negative findings in the HTR2C gene (À759C/T) that were published more recently were long-term studies in which patients had previously undergone extensive antipsychotic treatment. Thus, HTR2C may be more likely to be involved in the initial side effects of antipsychotic treatment. The rs7799039 promoter variant of the leptin gene was implicated in AIWG in every recent study we examined. However, there are conflicting results on whether the G or A allele confers susceptibility. Zhang et al. 110 reported significant association of the G allele in the male, but not in the female subgroup, and Gregoor et al. 112 observed that the G allele was associated with the occurrence of obesity in males, whereas the A allele was associated in females, inferring a potential sex-specific interaction. Moreover, Calarge et al. 113 found the A allele to be associated with increased BMI in adolescents, suggesting a possible effect of age or early onset. The disparity between these groups could be explained by different risk factors between genders and age, and replication is needed to investigate these effects.
There has also been progress in finding numerous novel variants. Previous investigations of the DRD2 gene have been negative; however, it is important to note that these investigations did not cover the gene using tag-SNPs. Two studies using tag-SNPs had found two novel markers that were associated in Asian and European-American samples. 57, 63 Thus, DRD2 is one of the most promising genes and should garner further research, including DNA sequencing. Furthermore, novel susceptibility genes, such as CNR1, MC4R, NPY, ADRA2A and the INSIG2 genes have also shown promising results that need to be replicated in further studies.
The mixed results in some of the pharmacogenetic studies are likely a reflection of limitations derived from biological complexity of AIWG, potential nongenetic confounders of AIWG and the design of candidate gene studies. It is likely that each risk allele contributes only a small proportion of the variation predisposing an individual to treatmentemergent side effects. Studies focusing on a few polymorphisms in a single gene may not be able to detect an effect. In addition, environmental factors that may be linked to AIWG are poorly understood and could potentially confound results. Patients with premorbid weight below average BMI have been reported to gain the most weight, whereas patients with above-average BMI at the start of antipsychotic treatment have the least weight gain and this should be taken account in future studies. 154 Other factors influencing AIWG include gender and age, [154] [155] [156] as well as smoking, which may also further increase the risk for cardiovascular disease (for a detailed discussion, see McCreadie ). Furthermore, to the best of our knowledge, no studies have examined epigenetic factors, such as methylation status or histone acetylation, which can profoundly alter gene expression.
Despite these limitations, new approaches are beginning to be used to increase specificity and quality of results. Ruañ o et al. 115 used a novel method of statistical analysis called physiogenomics to adequately handle comprehensive genomic data and enhance statistical power. Using this method, the authors elucidated an independent set of risk factors for patients receiving different SGAs. Risperidoneinduced weight gain was associated with appetite peptide genes (LEPR, NPRY5 and PON1). In contrast, olanzapine-induced weight gain was reported in the genes involved in lipid metabolism (APO3, APOA4 and SCARB1; Table 2 ). Le Hellard et al. 142 used a functional convergent genomic approach in which the five genes in the lipid biosynthesis pathway were analyzed using tagging SNPs. This strategy allowed for a detailed characterization of genomic function in the lipid biosynthesis pathway. Such methodology may be used as a paradigm for future personalized genetics screening algorithms. Liu et al. 80 studied the ADRA1A gene exhaustively using tag-SNPs to discover that most SNPs that are associated with changes in BMI are located in promoter and intron regions rather than missense mutations. The advantage of this approach is better characterization of the full variation in a single gene. Our group 139 performed tag-SNP analysis on the CNR1 gene. In addition, we used an electromobility shift assay to identify a transcription factor-binding site; thereby comprehensively studying the CNR1 gene, and providing functional relevance to the findings. GWAS in AIWG and in obesity can be regarded as a complimentary approach to candidate gene studies, which may allow identifying novel candidates and chromosomal regions of interest. GWASs on AIWG have generated first interesting findings such as the MEIS and MC4R genes ( Table 2 ). The increase in sophistication of these studies provides a better understanding of how these genes relate to AIWG, thereby enhancing previous findings, and overcoming limitations of traditional candidate genes studies. Therefore, these approaches are likely to set a new standard for future analysis.
Clinical implications
Given the findings to date, the increased conceptual understanding of AIWG from past studies, and the novel developments in research strategies and techniques, it could be argued that the personalized prescription based on genetic screening is very promising with application in the near future. Indeed, pharmacogenetics has arguably progressed faster in psychiatry than in any other field with the exception of perhaps oncology. Challenges to introducing individualized DNA pharmacogenetic tests in a clinical environment remain, although first steps have already been taken.
Genetic screens with sufficient sensitivity and specificity need to be developed. Recently, a DNAbased screen was developed for clozapine-induced agranulocytosis with high specificity (98%). However, the sensitivity was below a threshold necessary for clinically meaningful screens (20%). 158 By contrast, there is a much greater understanding of the genetic basis of AIWG indicating that screening for weight gain side effects could achieve greater sensitivity. These tests would also require insights into biocomputational analysis to build an algorithm incorporating genetic and non-genetic factors. The neuro-fuzzy model, which incorporates artificial neural networks and fuzzy logic, has recently been used by Lan et al. 159 in predicting 93% of SCZ patients with weight gain under antipsychotic treatment. This model suggests that pharmacogenetic testing is a feasible prediction tool for AIWG.
The ethical challenges are another imminent factor that needs to be addressed to avoid genetic discrimination by health professionals, insurance companies and caregivers. For instance, the pleiotropic effect of many gene variants will create particular challenges. The education of physicians and caregivers is also necessary to provide guidelines on how to communicate genetic findings.
In conclusion, with economically feasible DNA tests already available, pharmacogenetics holds substantial promise in predicting treatment emergence side effects and advancing the field of personalized medicine. Physicians currently prescribe medication based on the average properties of drugs in clinical trials. Pharmacogenetics will provide rational treatment based on matching antipsychotics to a patient's DNA profile, thus, potentially providing effective treatment with minimal side effects to outliers and mean responders to a given antipsychotic medication. With the culminating and continuing interest in pharmacogenetic analysis of AIWG, we are confident that personalized pharmacotherapy preventative of iatrogenic metabolic side effects will be available in the coming years.
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